Interleukin Genetics Inc. develops and markets proprietary genetic tests for chronic diseases and health-related conditions, and for informing lifestyle choices to facilitate wellness. Our tests provide information that is not otherwise available to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance. We leverage our research, intellectual property, and genetic test development expertise in inflammation and metabolism to identify individuals whose risk for certain chronic diseases may be increased due to variants in one or more genes, which can enable a more personalized approach to the individual’s healthcare. We market our tests through healthcare professionals, partnerships with health and wellness companies, and through other distribution channels. Our lead products are our proprietary cardiovascular risk test and the ILUSTRA™ Inflammation Management Program (the “ILUSTRA Program”), which includes the ILUSTRA Genetic Risk Test (the “ILUSTRA Test”, formerly referred to as the PerioPredict® Genetic Risk Test) that identifies individuals with a life-long predisposition to over-produce inflammation and our Inherent Health® line of genetic tests We continue to support the ILUSTRA Program deployments with customers and will advance new customer relationships that expand the evidence base of this program’s effectiveness.
Company profile
Ticker
ILIU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Medical Science Systems Inc
SEC CIK
Corporate docs
IRS number
943123681
Latest filings (excl ownership)
15-12B
Securities registration termination
14 Aug 17
25
Voluntary exchange delisting
4 Aug 17
DEF 14A
Definitive proxy
4 Aug 17
8-K
Regulation FD Disclosure
24 Jul 17
8-K
Interleukin Genetics To Explore Strategic Alternatives, Reduce Workforce
3 Jul 17
10-Q
2017 Q1
Quarterly report
11 May 17
10-K/A
2016 FY
Annual report (amended)
18 Apr 17
10-K
2016 FY
Annual report
17 Apr 17
424B3
Prospectus supplement
3 Apr 17
Latest ownership filings
SC 13D/A
Interleukin Genetics Inc
4 Aug 17
4
Stephan Toutain
12 May 17
4
Stephan Toutain
26 Jan 17
4
KENNETH S KORNMAN
26 Jan 17
4
JAMES M WEAVER
26 Jan 17
4
Mark B Carbeau
26 Jan 17
4
William C. Mills III
26 Jan 17
SC 13D/A
Interleukin Genetics Inc
5 Jan 17
4/A
Mark B Carbeau
7 Nov 16
4
Stephan Toutain
21 Oct 16
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|